Last 7 days
2.0%
Last 30 days
-0.5%
Last 90 days
4.0%
Trailing 12 Months
14.2%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 304.8B | 1.4B | -3.73% | 61.04% | -152.12 | 215.28 | 20.37% | -37.45% |
ABBV | 275.0B | 58.1B | 0.21% | 1.63% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 80.1B | 12.2B | -0.48% | 14.17% | 18.47 | 6.58 | -24.26% | -46.28% |
VRTX | 77.3B | 8.9B | -1.64% | 19.14% | 23.26 | 8.65 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -16.46% | 21.47% | -20.78 | 22.66 | 22.88% | -32.64% |
SRPT | 13.2B | 933.0M | 21.02% | 90.98% | -18.71 | 14.11 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -15.04% | 21.63% | 13.93 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.5B | 504.0K | -6.48% | 165.34% | -15.07 | 2.5K | -66.53% | -22.12% |
RARE | 2.8B | 363.3M | -7.03% | -36.05% | -3.99 | 7.77 | 3.39% | -55.81% |
BPMC | 2.7B | 204.0M | 2.71% | -22.88% | -4.84 | 13.22 | 13.30% | 13.44% |
MRTX | 2.5B | 12.4M | -10.70% | -44.17% | -3.35 | 199.44 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.6B | 191.8M | -7.72% | 90.19% | 24.49 | 8.55 | 43.59% | 60.82% |
MGNX | 429.6M | 93.0M | -0.16% | -22.78% | -2.25 | 4.62 | -19.83% | -30.37% |
CRBP | 24.0M | - | -31.83% | 665.59% | -0.57 | 19.11 | -77.61% | 7.22% |
CYTK | 3.5M | 94.6M | -15.04% | 9.81% | -0.01 | 0.04 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -11.2% | 12,173 | 13,710 | 14,227 | 16,508 | 16,072 |
S&GA Expenses | 5.0% | 2,116 | 2,015 | 1,931 | 1,869 | 1,825 |
R&D Expenses | 9.3% | 3,593 | 3,287 | 3,041 | 2,961 | 2,860 |
Costs and Expenses | -0.6% | 7,434 | 7,478 | 7,372 | 7,416 | 7,125 |
EBITDA | -17.9% | 5,260 | 6,409 | 6,696 | 9,483 | 9,669 |
EBITDA Margin | -7.6% | 0.43* | 0.47* | 0.45* | 0.57* | 0.60* |
Earnings Before Taxes | -19.5% | 4,859 | 6,038 | 6,344 | 9,134 | 9,326 |
EBT Margin | -9.4% | 0.40* | 0.44* | 0.42* | 0.55* | 0.58* |
Interest Expenses | 5.9% | 59.00 | 56.00 | 55.00 | 56.00 | 57.00 |
Net Income | -19.2% | 4,338 | 5,370 | 5,687 | 7,934 | 8,075 |
Net Income Margin | -9.0% | 0.36* | 0.39* | 0.38* | 0.48* | 0.50* |
Free Cahsflow | -11.5% | 5,015 | 5,668 | 8,452 | 8,515 | 7,081 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 5.6% | 29,215 | 27,678 | 27,206 | 26,349 | 25,435 |
Current Assets | 3.0% | 15,884 | 15,429 | 15,530 | 14,306 | 14,015 |
Cash Equivalents | -11.0% | 3,106 | 3,491 | 3,395 | 3,346 | 2,886 |
Inventory | -0.4% | 2,402 | 2,412 | 2,219 | 1,992 | 1,951 |
Net PPE | 1.8% | 3,704 | 3,638 | 3,556 | 3,482 | - |
Liabilities | 5.0% | 6,551 | 6,239 | 6,518 | 6,434 | 6,666 |
Current Liabilities | 9.1% | 3,141 | 2,879 | 3,034 | 3,008 | 3,933 |
Long Term Debt | -10.3% | 1,513 | 1,686 | 1,887 | - | - |
LT Debt, Non Current | 0.0% | 1,981 | 1,981 | 1,981 | 1,980 | 1,980 |
Shareholder's Equity | 5.7% | 22,664 | 21,439 | 20,688 | 19,915 | 18,769 |
Retained Earnings | 5.4% | 23,307 | 22,110 | 20,794 | 19,942 | 18,968 |
Additional Paid-In Capital | 4.5% | 9,949 | 9,518 | 9,120 | 8,754 | 8,088 |
Shares Outstanding | -0.9% | 107 | 108 | 107 | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -11.5% | 5,015 | 5,668 | 8,452 | 8,515 | 7,081 |
Share Based Compensation | 6.4% | 725 | 681 | 652 | 638 | 602 |
Cashflow From Investing | 3.9% | -3,784 | -3,939 | -6,570 | -6,031 | -5,384 |
Cashflow From Financing | 39.5% | -1,009 | -1,668 | -557 | -574 | -1,005 |
Buy Backs | -17.5% | 2,083 | 2,526 | 1,803 | 1,698 | 1,645 |
71.2%
35.8%
6.5%
Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.
16.0%
10.9%
17.2%
17.8%
FIve years rolling returns for Regeneron Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -23.00 | -224,477 | 937,523 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -1.83 | 1,789,050 | 65,144,100 | 0.07% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 1,910 | 33,910 | -% |
2023-03-10 | MATHER GROUP, LLC. | added | 3.41 | 19,139 | 241,139 | -% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | unchanged | - | 14,671 | 324,671 | 0.05% |
2023-03-06 | OLD MISSION CAPITAL LLC | sold off | -100 | -338,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -6.7 | -1,274,000 | 54,461,000 | 0.27% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | new | - | 202,017 | 202,017 | 0.01% |
2023-03-03 | TIAA, FSB | added | 50.62 | 735,350 | 2,009,350 | 0.01% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 9,088,600 | 9,088,600 | 0.11% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital world investors | 5.9% | 6,315,819 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.15% | 8,722,448 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.6% | 9,166,817 | SC 13G/A | |
Jan 11, 2023 | jpmorgan chase & co | 5.6% | 6,101,044 | SC 13G | |
Feb 11, 2022 | capital world investors | 5.1% | 5,391,870 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 7.72% | 8,158,515 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 9.1% | 9,610,871 | SC 13G/A | |
Feb 16, 2021 | capital world investors | 6.7% | 7,017,122 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 1024.59 36.66% | 1399.74 86.69% | 1972.26 163.06% | 2986.22 298.30% | 3604.06 380.70% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Feb 24, 2023 | 4 | Insider Trading | |
Feb 14, 2023 | 4 | Insider Trading | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 08, 2023 | 4 | Insider Trading | |
Feb 08, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-10 | LAROSA JOSEPH J | gifted | - | - | -1,006 | evp general counsel and secret |
2023-03-01 | RYAN ARTHUR F | sold | -76,249 | 762 | -100 | - |
2023-03-01 | McCourt Marion | acquired | 409,706 | 372 | 1,100 | evp commercial |
2023-03-01 | McCourt Marion | sold | -835,879 | 759 | -1,100 | evp commercial |
2023-02-22 | VAGELOS P ROY | sold (taxes) | -21,758,400 | 750 | -29,005 | - |
2023-02-22 | VAGELOS P ROY | acquired | 11,493,300 | 270 | 42,500 | - |
2023-02-12 | McCourt Marion | sold (taxes) | -959,271 | 751 | -1,276 | evp commercial |
2023-02-07 | McCourt Marion | sold | -769,040 | 769 | -1,000 | evp commercial |
2023-02-07 | McCourt Marion | acquired | 372,460 | 372 | 1,000 | evp commercial |
2023-02-06 | GOLDSTEIN JOSEPH L | acquired | 1,743,920 | 482 | 3,613 | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Revenues | $ 2,936.2 | $ 3,452.8 | $ 8,758.5 | $ 11,120.0 |
Expenses: | ||||
Research and development | 911.3 | 665.4 | 2,549.4 | 2,122.5 |
Acquired in-process research and development | 0.0 | 0.0 | 225.1 | 0.0 |
Selling, general, and administrative | 529.1 | 445.0 | 1,455.4 | 1,265.3 |
Other operating (income) expense, net | (45.7) | 42.0 | (83.3) | (29.8) |
Costs and expenses, total | 1,712.5 | 1,605.6 | 5,166.4 | 4,812.9 |
Income from operations | 1,223.7 | 1,847.2 | 3,592.1 | 6,307.1 |
Other income (expense): | ||||
Other income (expense), net | 301.4 | (16.4) | (16.0) | 558.5 |
Interest expense | (15.3) | (14.2) | (42.0) | (43.2) |
Total other income (expense) | 286.1 | (30.6) | (58.0) | 515.3 |
Income before income taxes | 1,509.8 | 1,816.6 | 3,534.1 | 6,822.4 |
Income tax expense | 194.1 | 184.4 | 392.8 | 976.1 |
Net income | $ 1,315.7 | $ 1,632.2 | $ 3,141.3 | $ 5,846.3 |
Net income per share - basic (in dollars per share) | $ 12.31 | $ 15.37 | $ 29.30 | $ 55.42 |
Net income per share - diluted (in dollars per share) | $ 11.66 | $ 14.33 | $ 27.73 | $ 52.29 |
Weighted average shares outstanding - basic (in shares) | 106.9 | 106.2 | 107.2 | 105.5 |
Weighted average shares outstanding - diluted (in shares) | 112.8 | 113.9 | 113.3 | 111.8 |
Statements of Comprehensive Income | ||||
Net income | $ 1,315.7 | $ 1,632.2 | $ 3,141.3 | $ 5,846.3 |
Other comprehensive income (loss), net of tax: | ||||
Unrealized loss on debt securities | (51.3) | (6.4) | (249.9) | (20.5) |
Unrealized gain on cash flow hedges | 0.0 | 0.2 | 1.0 | 0.7 |
Comprehensive income | 1,264.4 | 1,626.0 | 2,892.4 | 5,826.5 |
Net product sales | ||||
Revenues: | ||||
Revenues | 1,801.4 | 2,279.9 | 5,194.4 | 8,142.0 |
Expenses: | ||||
Cost of goods, collaboration and contract manufacturing | 141.3 | 238.8 | 497.8 | 961.4 |
Collaboration revenue | ||||
Revenues: | ||||
Revenues | 1,050.6 | 1,073.9 | 3,326.7 | 2,783.0 |
Other revenue | ||||
Revenues: | ||||
Revenues | 84.2 | 99.0 | 237.4 | 195.0 |
Cost of collaboration and contract manufacturing | ||||
Expenses: | ||||
Cost of goods, collaboration and contract manufacturing | $ 176.5 | $ 214.4 | $ 522.0 | $ 493.5 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,491.3 | $ 2,885.6 |
Marketable securities | 3,530.4 | 2,809.1 |
Accounts receivable, net | 5,548.3 | 6,036.5 |
Inventories | 2,412.2 | 1,951.3 |
Prepaid expenses and other current assets | 446.4 | 332.4 |
Total current assets | 15,428.6 | 14,014.9 |
Marketable securities | 5,968.6 | 6,838.0 |
Property, plant, and equipment, net | 3,704.2 | 3,482.2 |
Intangible assets, net | 804.1 | 6.7 |
Deferred tax assets | 1,452.1 | 876.9 |
Other noncurrent assets | 320.2 | 216.1 |
Total assets | 27,677.8 | 25,434.8 |
Current liabilities: | ||
Accounts payable | 535.6 | 564.0 |
Accrued expenses and other current liabilities | 1,796.4 | 2,206.8 |
Finance lease liabilities | 0.0 | 719.7 |
Deferred revenue | 547.2 | 442.0 |
Total current liabilities | 2,879.2 | 3,932.5 |
Long-term debt | 1,981.1 | 1,980.0 |
Finance lease liabilities | 720.0 | 0.0 |
Deferred revenue | 60.1 | 73.3 |
Other noncurrent liabilities | 598.6 | 680.2 |
Total liabilities | 6,239.0 | 6,666.0 |
Stockholders' equity: | ||
Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none | 0.0 | 0.0 |
Additional paid-in capital | 9,518.2 | 8,087.5 |
Retained earnings | 22,109.6 | 18,968.3 |
Accumulated other comprehensive loss | (275.1) | (26.2) |
Treasury Stock, at cost; 22.0 shares in 2022 and 19.4 shares in 2021 | (9,914.0) | (8,260.9) |
Total stockholders' equity | 21,438.8 | 18,768.8 |
Total liabilities and stockholders' equity | 27,677.8 | 25,434.8 |
Class A Stock | ||
Stockholders' equity: | ||
Common stock | 0.0 | 0.0 |
Common Stock | ||
Stockholders' equity: | ||
Common stock | $ 0.1 | $ 0.1 |